XORTX Delists from TSX Venture

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, has announced its decision to voluntarily delist its common shares from the TSX Venture Exchange. This strategic move aims to reduce duplicative exchange fees, legal and accounting expenses, and regulatory complexity associated with maintaining a dual listing. The company believes this will allow for greater management focus on its XRx-026 program for gout treatment and enhance long-term shareholder value. All shareholders, including Canadian shareholders, will continue to have full trading access to their common shares on Nasdaq-100. The delisting was approved by XORTX Therapeutics Inc.'s Board of Directors and does not require shareholder approval as the shares are listed on an acceptable alternative market. XORTX Therapeutics Inc. will remain a reporting issuer under applicable securities laws in Canada — Alberta, Canada — British Columbia, and Canada — Ontario.